- Systematic review of metabolomic profiles linked to liver cancer
-
Tran BLT, Cao NH, Hoang T
- KMID: 2579961
- J Liver Cancer.
- 2026 Mar;26(1):124-146.
- doi: 10.17998/jlc.2025.10.27
Backgrounds/Aims: Increasing evidence indicates that metabolites play a significant role in the pathogenesis of liver cancer and have potential as biomarkers for early detection. This review summarizes the current literature... -
- CITED
-
- Close
- SHARE
-
- Close
- Exploring single-cell and multi-omics technologies and their role in unraveling tumor heterogeneity of hepatocellular carcinoma
-
Jyotishi C, Prajapati S, Patel M, Gupta R
- KMID: 2579960
- J Liver Cancer.
- 2026 Mar;26(1):104-123.
- doi: 10.17998/jlc.2025.11.29
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Tumor heterogeneity is a major obstacle to effective treatment and is poorly understood using traditional bulk sequencing methods.... -
- CITED
-
- Close
- SHARE
-
- Close
- Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches
-
Choi SK, Woo S, Chon HJ
- KMID: 2579957
- J Liver Cancer.
- 2026 Mar;26(1):65-82.
- doi: 10.17998/jlc.2025.12.21
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. The recent introduction of immune checkpoint inhibitors (ICIs) has transformed the therapeutic landscape for advanced HCC. Combination regimens such... -
- CITED
-
- Close
- SHARE
-
- Close
- Liver resection versus radiofrequency ablation or transarterial chemoembolization for early multinodular BCLC-A hepatocellular carcinoma: a systematic review and meta-analysis
-
Viana MFF, Braga AA, Carvalho LB, Vasconcellos DCMS, Alexandrino BCMR, Coimbra FJF
- KMID: 2579963
- J Liver Cancer.
- 2026 Mar;26(1):157-168.
- doi: 10.17998/jlc.2026.02.21
Backgrounds/Aims: Hepatocellularcarcinoma (HCC) is the most common form of liver cancer, with high mortality rates worldwide. The optimal treatment strategy for patients with multinodular early-stage HCC (BCLC-A) is still controversial,... -
- CITED
-
- Close
- SHARE
-
- Close
- Surgical management of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a narrative review of principles, technical nuances, and emerging strategies
-
Lee W, Hong KP, Lee JH, Lee M, Sung M, Lee SJ, Song KB, Hwang DW, Kim SC
- KMID: 2579952
- J Liver Cancer.
- 2026 Mar;26(1):19-28.
- doi: 10.17998/jlc.2026.01.24
Intrahepatic cholangiocarcinoma (CCA) is the second most common primary liver cancer after hepatocellular carcinoma (HCC). However, combined HCC-CCA is a rare malignancy exhibiting hepatocytic and cholangiocytic differentiation. For both tumors,... -
- CITED
-
- Close
- SHARE
-
- Close
- Re-evaluating DAA therapy in active hepatocellular carcinoma: from controversy to clinical considerations
-
Jeon SH, Yoo JJ, Kim SG, Kim YS
- KMID: 2579959
- J Liver Cancer.
- 2026 Mar;26(1):93-103.
- doi: 10.17998/jlc.2025.11.17
Direct-acting antiviral (DAA) therapy has brought a revolution to the management of chronic hepatitis C virus infection, but its role in patients with active hepatocellular carcinoma (HCC) remains controversial. Early... -
- CITED
-
- Close
- SHARE
-
- Close
- PNPLA3 I148M is unrelated to HCC occurrence but associates with poorer tumor differentiation in Korean MASLD: a prospective cohort of 562 patients
-
Lee J, Lee DY, Cha JH, Cho HS, Yang K, Yang H, Byun MY, Cho SK, Yang SW, Bae SH, Sung PS
- KMID: 2579962
- J Liver Cancer.
- 2026 Mar;26(1):147-156.
- doi: 10.17998/jlc.2025.11.16
Backgrounds/Aims: The patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M variant has been implicated in metabolic dysfunction-associated steatotic liver disease (MASLD), but its role in hepatocellular carcinoma (HCC) development is unclear.... -
- CITED
-
- Close
- SHARE
-
- Close
- Contemporary overview of liver transplantation for intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma
-
Lee HW
- KMID: 2579953
- J Liver Cancer.
- 2026 Mar;26(1):29-35.
- doi: 10.17998/jlc.2026.03.03
Historically, intrahepatic cholangiocarcinoma (iCCA) and combined hepatocellular-cholangiocarcinoma (cHCC-CCA) were regarded as absolute contraindications for liver transplantation (LT) due to dismal outcomes characterized by high recurrence rates and poor long-term survival... -
- CITED
-
- Close
- SHARE
-
- Close
- Imaging differentiation of hepatocellular carcinoma, combined hepatocellular-cholangiocarcinoma, and intrahepatic cholangiocarcinoma: pitfalls and advances
-
Shin J, Chung T, Ha SY, Rhee H
- KMID: 2579951
- J Liver Cancer.
- 2026 Mar;26(1):9-18.
- doi: 10.17998/jlc.2026.03.05
Accurate non-invasive differentiation of primary liver cancers, such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and combined hepatocellular-cholangiocarcinoma (cHCC-CCA), is crucial for optimal management but challenging due to shared risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Combined hepatocellular-cholangiocarcinoma: a contemporary pathologic and molecular perspective
-
Chung T
- KMID: 2579950
- J Liver Cancer.
- 2026 Mar;26(1):1-8.
- doi: 10.17998/jlc.2026.03.06
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma characterized by the unequivocal coexistence of hepatocytic and cholangiocytic differentiation within a single tumor. Despite its low incidence, cHCC-CCA has... -
- CITED
-
- Close
- SHARE
-
- Close
- Systemic treatment strategies for combined hepatocellular-cholangiocarcinoma: current evidence and future direction
-
Yoon J
- KMID: 2579955
- J Liver Cancer.
- 2026 Mar;26(1):45-54.
- doi: 10.17998/jlc.2026.02.24
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy characterized by biphenotypic differentiation and marked biologic heterogeneity. Owing to its low incidence, diagnostic complexity, and lineage plasticity, standardized systemic treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- The role of radiotherapy in the management of combined hepatocellular-cholangiocarcinoma: current evidence and future perspectives
-
Choi SH, Koom WS, Lee IJ
- KMID: 2579956
- J Liver Cancer.
- 2026 Mar;26(1):55-64.
- doi: 10.17998/jlc.2026.03.04
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare and highly aggressive hybrid malignancy characterized by a poor prognosis and high recurrence rates due to its dual histological nature. In the absence of... -
- CITED
-
- Close
- SHARE
-
- Close
- A rare case of IgG4-related sclerosing cholangitis followed by rapid subsequent diagnosis of cholangiocarcinoma
-
Hong G, Hussain A, Correia ETdO, Shalaby A, Bittencourt LK, Mahipal A, Ocuin LM, Sclair SN
- KMID: 2579964
- J Liver Cancer.
- 2026 Mar;26(1):169-175.
- doi: 10.17998/jlc.2025.12.09
Immunoglobulin G4 (IgG4)-related sclerosing cholangitis (IgG4-SC) is a rare condition with symptoms often mimicking malignancy, infection, or other autoimmune diseases. This case report describes the unique case of a 62-year-old... -
- CITED
-
- Close
- SHARE
-
- Close
- Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy
-
Hong JY, Sinn DH, Ha SY
- KMID: 2579954
- J Liver Cancer.
- 2026 Mar;26(1):36-44.
- doi: 10.17998/jlc.2026.03.02
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver malignancy exhibiting both hepatocytic and cholangiocytic differentiation. Since the 2019 World Health Organization (WHO) reclassification, growing molecular and clinical evidence has reshaped... -
- CITED
-
- Close
- SHARE
-
- Close
- Alcohol-related hepatocellular carcinoma: surveillance and primary prevention
-
Testino G
- KMID: 2579965
- J Liver Cancer.
- 2026 Mar;26(1):176-177.
- doi: 10.17998/jlc.2025.09.16
-
- CITED
-
- Close
- SHARE
-
- Close
- Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib
-
Iwamoto H, Shimose S, Koga H, Kawaguchi T
- KMID: 2579958
- J Liver Cancer.
- 2026 Mar;26(1):83-92.
- doi: 10.17998/jlc.2025.12.12
The emergence of systemic therapies has ushered in an era of chemo-diversity for hepatocellular carcinoma, in which drug sequencing is pivotal for maximizing outcomes. Among available agents, lenvatinib is notable... -
- CITED
-
- Close
- SHARE
-
- Close
